Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib)
Preliminary safety trial results show an increased risk of serious heart-related problems and cancer with Xeljanz, Xeljanz XR (tofacitinib). FDA will evaluate the results. Patients should not stop taking the medicine without first talking to their health care professionals.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: FDA Source Type: news
More News: Arthritis | Cancer | Cancer & Oncology | Cardiology | Drugs & Pharmacology | Health Management | Heart | Inflammatory Bowel Disease | Rheumatology | Ulcerative Colitis